The Global Recombinant Proteins Market size is expected to reach $2.6 billion by 2028, rising at a market growth of 10.8% CAGR during the forecast period.
Recombinant proteins have a huge future in the study and development of cancer therapies. Examples of recombinant proteins used in cancer therapy research include growth factors, immunological checkpoints, and cell damage & oxidative stress proteins (preclinical stage). The utilization of recombinant proteins including immunological checkpoint, antibodies, andgrowth factors, for targeted purposes has risen because of a greater knowledge of neoplastic signalling cascades and the proteins involved in them.
Researchers utilise these proteins frequently to study how cancer signalling pathways and functions. Research uses recombinant immune checkpoints that directly target programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1), includingPD-1/PD-L1 Inhibitor 1 and PD-1/PD-L1 Inhibitor 2. Aside from that, proteins like CD40 Ligand/TRAP, CD226, and Human CellExp CTLA4/CD152 are often employed in studies on cancer therapy.
Growth in the business is predicted to be fueled by the increased incidence of chronic disorders such granulomatous disease, haemophilia, and sclerosis. Additionally, improved recombinant protein products, the growing preference for biologics and biosimilars, and other reasons all contribute to the industry"s expansion. The race to discover cures and diagnostic tools for the SARS-CoV2 virus was fuelled by the COVID-19 epidemic.
With over 400 million people worldwide suffer from uncommon genetic illnesses, according to Global Genes. This figure demonstrates the urgent need for therapies, an improvement in healthcare environments, and increased public knowledge of health issues. A critical instrument for the creation of medicines is the requirement for cutting-edge research and knowledge of drug targeting mechanisms.
Cohort programmes have helped several regions create biobanks that give researchers access to high-quality samples that will revolutionise treatment efforts. This may lead to a greater emphasis on the identification of biomarkers for various illnesses. As an illustration, the FDA approved Ayvakit in August 2022 to address advanced systemic mastocytosis, a rare blood disorder.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Recombinant proteins have a huge future in the study and development of cancer therapies. Examples of recombinant proteins used in cancer therapy research include growth factors, immunological checkpoints, and cell damage & oxidative stress proteins (preclinical stage). The utilization of recombinant proteins including immunological checkpoint, antibodies, andgrowth factors, for targeted purposes has risen because of a greater knowledge of neoplastic signalling cascades and the proteins involved in them.
Researchers utilise these proteins frequently to study how cancer signalling pathways and functions. Research uses recombinant immune checkpoints that directly target programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1), includingPD-1/PD-L1 Inhibitor 1 and PD-1/PD-L1 Inhibitor 2. Aside from that, proteins like CD40 Ligand/TRAP, CD226, and Human CellExp CTLA4/CD152 are often employed in studies on cancer therapy.
Growth in the business is predicted to be fueled by the increased incidence of chronic disorders such granulomatous disease, haemophilia, and sclerosis. Additionally, improved recombinant protein products, the growing preference for biologics and biosimilars, and other reasons all contribute to the industry"s expansion. The race to discover cures and diagnostic tools for the SARS-CoV2 virus was fuelled by the COVID-19 epidemic.
With over 400 million people worldwide suffer from uncommon genetic illnesses, according to Global Genes. This figure demonstrates the urgent need for therapies, an improvement in healthcare environments, and increased public knowledge of health issues. A critical instrument for the creation of medicines is the requirement for cutting-edge research and knowledge of drug targeting mechanisms.
Cohort programmes have helped several regions create biobanks that give researchers access to high-quality samples that will revolutionise treatment efforts. This may lead to a greater emphasis on the identification of biomarkers for various illnesses. As an illustration, the FDA approved Ayvakit in August 2022 to address advanced systemic mastocytosis, a rare blood disorder.
COVID-19 Impact Analysis
The requirement for the COVID-19 vaccine to be developed quickly and on a large scale, as well as its ongoing commercial manufacturing activities, had a favourable effect on the development of biologics-based research initiatives and ultimately helped the industry"s expansion. The COVID-19 pandemic had a favourable effect on the expansion of the proteins market. Recombinant protein vaccines may be developed with a combination of subunits of different adjuvants and antigens that will be more effective against SARS-CoV-2 infections and be readily available in the centre, it was suggested in light of the growth in COVID infection.Market Growth Factors
Growing Emphasis On Customized Medicine Due To An Increase In The Prevalence Of Chronic Diseases
The market for recombinant proteins is anticipated to expand in demand due to the increased research and development on biologics. The R&D industry has traditionally required a lot of capital because of lengthy study periods and regulatory delays. Consumption on R&D accounts for a considerable share of global spending. Governments acknowledge R&D as a crucial factor in a nation"s development, global competitiveness, and public good. R&D funding and spending have risen steadily as a result.Increasing Biologics Research And Development
Semiconductor electronic devices are usually covered with a protective enclosure to surround the internal components and protect them from any adverse condition. These enclosures are created based on different fabrication methods to form a final product in a single sheet, preferably made of aluminum alloys. Anodic Aluminum Oxide-nanopores (AAO-np) structures fabricated on the aluminum alloy using a two-step anodizing process are known to exhibit good crystallinity with an oxide layer.Market Restraining Factor
Recombinant proteins are getting cheaper
Recombinant proteins are made in labs using cells that have been grown, which contributes to their expensive price. Purification of these medications, which can make up as much as 80% of the manufacturing costs, is one of the major expenses. Price erosion is defined as when many players enter a particular market and sell identical products without any uniqueness, saturating the market with less creative and reasonably priced goods. Price erosion is the constant drop in the price of these products in each market, which slows down market expansion.Product Outlook
Based on Product, the market for recombinant proteins is classified into growth factors and chemokines, immune response proteins, structural proteins, membrane proteins, kinase proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. Immune response proteins are expected to command a sizable sales share in 2021. A crucial group of proteins in the body are cytokines. These little proteins act as immune system messengers. They serve as the immune system"s network of communication and are created in reaction to a threat. Immune system cells can sometimes interact by touching one another directly, but more frequently, they do so via secreting cytokines, which can operate on other cells nearby or far away.
Application Outlook
Based on application, the market Drug Discovery & Development, Biopharmaceutical Production, Biotechnology Research, Academic Research Studies, Diagnostics, and Other Applications. The biotechnology research command a significant revenue share in 2021. Recombinant proteins aid in illuminating an organism"s basic and underlying principles. These molecules can be used to identify and pinpoint the location of the protein that a particular gene encodes, as well as to learn more about how other genes are involved in processes such as cell signalling, metabolism, growth, replication, and death, as well as translation, transcription, and protein modification.End-user Outlook
Based on End-user, the Recombinant Proteins Market is divided in pharmaceutical and biopharmaceutical industry, biotechnology industry, academic research institutes, contract research organisations, and other end users. Contract Research Organizations are expected to account for a sizable portion of market revenue in 2021. The R&D industry saw increased investments in regards to partnerships and collaborations between academic institutions and businesses. For instance, the Center for Therapeutic Innovation (CTI) at Pfizer serves as a forum for interaction among stakeholders in the healthcare system.Regional Outlook
Based on geography, the Recombinant Proteins Market is classified into North America, Europe, Asia Pacific, and LAMEA. The leading regional market for recombinant proteins in 2021 was North America. The high prevalence of chronic and genetic diseases, the availability of funding for R&D, government initiatives for R&D in the pharmaceutical industry, the growing use of life science techniques in research and academia, the significant presence of major pharmaceutical and biotechnology organizations, and the application of analytical instruments in drug discovery and development are all factors that contribute to North America holding a significant share of the global market.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Strategies Deployed in Recombinant Proteins Market
- Nov-2022: Abcam comes into agreement with NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research. Through this agreement, Abcam RabMAb™ recombinant antibodies would be produced as part of the first 64-plex protein panel for NanoString’s CosMx™ Spatial Molecular Imager (SMI). Additionally, this agreement would open the full capability of spatial biology and help enhance care for people with cancer.
- 2022-Jul: Bio-Rad Laboratories launched EconoFit Columns, a low-pressure prepacked chromatography column pack. The EconoFit columns are created for resin screening, enabling customers that are designing protein purification workflows to choose the optimal chemistry for various targets. The products offer run-to-run uniformity to support preparative scale purifications and method advancement for the latest target proteins, as well as to improve existing workflows.
- Feb-2022: Abcam came into agreement with Twist Bioscience Corporation, a synthetic biology company. Under this agreement, Abcam would use a proprietary Twist VHH phage library for antibody development, discovery, and commercialization for research and diagnostic application. Moreover, Twist Bioscience grants Abcam the right to perform research and development activities utilizing Twist single domain (VHH) synthetic antibody library.
- Jan-2022: Thermo Fisher Scientific Inc. completed the acquisition PeproTech, Inc., a leading developer, and manufacturer of recombinant proteins. Through this acquisition, PeproTech"s recombinant proteins suite aligns with Thermo Fisher"s cell culture media products and would allow Thermo Fisher to offer customers significant advantages through an integrated offering.
- 2021-Nov: Abcam partnered with Nautilus Biotechnology, Inc., a development-stage life sciences company. Under this partnership, Both companies would focus on the combined advancement of affinity binding reagents used on the Nautilus proteomic analysis system and would broaden in the upcoming time to the large-scale manufacturing and supply of reagents for production.
- Mar-2021: Bio-Techne Corporation released Cultrex™ UltiMatrix, a hydrogel extracellular matrix that is beneficial for cultivating pluripotent stem cells and organoids in terms of performance and consistency. The product develops Matriz hydrogels that support the growth use of pluripotent stem and organoid cells for drug research, commercialize medicine, and regenerative medicine.
- Nov-2020: Merck signed an agreement with Donghao Lansheng (Group) Co., Ltd., a large modern service industry. This agreement would drive a new process that helps the custom clearing of research material for analytical use and biomedical innovation, through this Merck would be able to process shipments with the technical dossier and fewer application needs.
- Nov-2019: Abcam plc announced a partnership with BrickBio, a Tiger Gene suite company and have specialization in site-specific protein modification. Through this partnership, Abcam would have full rights to the platform for the formation of novel conjugation-ready recombinant products for the research equipment market and to produce the platform over its recombinant antibody and protein offering for diagnostic use.
- Apr-2019: Bio-Techne Corporation Collaborated with Elpiscience BioPharma, a clinical-stage biopharmaceutical company. Through this collaboration, both companies aimed to advance anti-cancer therapeutics and boost the development of the latest biologics to meet the medical requirements in Oncology.
- Apr-2018: Proteintech Group acquired HumanZyme, a manufacturer of recombinant human proteins. Through this acquisition, the company would strengthen its place as a manufacturer of antibodies, ELISA kits, and proteins.
Scope of the Study
By Product
- Growth Factors & Chemokines
- Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors
- Structural Proteins
- Membrane Proteins
- Kinase Proteins & Regulatory Proteins
- Immune Response Proteins
- Others
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
By Application
- Drug Discovery & Development
- Academic Research Studies
- Biopharmaceutical Production
- Diagnostics
- Biotechnology Research
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Recombinant Proteins Market, by Product
1.4.2 Global Recombinant Proteins Market, by End User
1.4.3 Global Recombinant Proteins Market, by Application
1.4.4 Global Recombinant Proteins Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Recombinant Proteins Market
Chapter 4. Global Recombinant Proteins Market by Product
4.1 Global Growth Factors & Chemokines Market by Region
4.2 Global Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors Market by Region
4.3 Global Structural Proteins Market by Region
4.4 Global Membrane Proteins Market by Region
4.5 Global Kinase Proteins & Regulatory Proteins Market by Region
4.6 Global Immune Response Proteins Market by Region
4.7 Global Others Market by Region
Chapter 5. Global Recombinant Proteins Market by End User
5.1 Global Pharmaceutical & Biopharmaceutical Companies Market by Region
5.2 Global Biotechnology Companies Market by Region
5.3 Global Academic Research Institutes Market by Region
5.4 Global Contract Research Organizations Market by Region
5.5 Global Others Market by Region
Chapter 6. Global Recombinant Proteins Market by Application
6.1 Global Drug Discovery & Development Market by Region
6.2 Global Academic Research Studies Market by Region
6.3 Global Biopharmaceutical Production Market by Region
6.4 Global Diagnostics Market by Region
6.5 Global Biotechnology Research Market by Region
6.6 Global Others Market by Region
Chapter 7. Global Recombinant Proteins Market by Region
7.1 North America Recombinant Proteins Market
7.1.1 North America Recombinant Proteins Market by Product
7.1.1.1 North America Growth Factors & Chemokines Market by Country
7.1.1.2 North America Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors Market by Country
7.1.1.3 North America Structural Proteins Market by Country
7.1.1.4 North America Membrane Proteins Market by Country
7.1.1.5 North America Kinase Proteins & Regulatory Proteins Market by Country
7.1.1.6 North America Immune Response Proteins Market by Country
7.1.1.7 North America Others Market by Country
7.1.2 North America Recombinant Proteins Market by End User
7.1.2.1 North America Pharmaceutical & Biopharmaceutical Companies Market by Country
7.1.2.2 North America Biotechnology Companies Market by Country
7.1.2.3 North America Academic Research Institutes Market by Country
7.1.2.4 North America Contract Research Organizations Market by Country
7.1.2.5 North America Others Market by Country
7.1.3 North America Recombinant Proteins Market by Application
7.1.3.1 North America Drug Discovery & Development Market by Country
7.1.3.2 North America Academic Research Studies Market by Country
7.1.3.3 North America Biopharmaceutical Production Market by Country
7.1.3.4 North America Diagnostics Market by Country
7.1.3.5 North America Biotechnology Research Market by Country
7.1.3.6 North America Others Market by Country
7.1.4 North America Recombinant Proteins Market by Country
7.1.4.1 US Recombinant Proteins Market
7.1.4.1.1 US Recombinant Proteins Market by Product
7.1.4.1.2 US Recombinant Proteins Market by End User
7.1.4.1.3 US Recombinant Proteins Market by Application
7.1.4.2 Canada Recombinant Proteins Market
7.1.4.2.1 Canada Recombinant Proteins Market by Product
7.1.4.2.2 Canada Recombinant Proteins Market by End User
7.1.4.2.3 Canada Recombinant Proteins Market by Application
7.1.4.3 Mexico Recombinant Proteins Market
7.1.4.3.1 Mexico Recombinant Proteins Market by Product
7.1.4.3.2 Mexico Recombinant Proteins Market by End User
7.1.4.3.3 Mexico Recombinant Proteins Market by Application
7.1.4.4 Rest of North America Recombinant Proteins Market
7.1.4.4.1 Rest of North America Recombinant Proteins Market by Product
7.1.4.4.2 Rest of North America Recombinant Proteins Market by End User
7.1.4.4.3 Rest of North America Recombinant Proteins Market by Application
7.2 Europe Recombinant Proteins Market
7.2.1 Europe Recombinant Proteins Market by Product
7.2.1.1 Europe Growth Factors & Chemokines Market by Country
7.2.1.2 Europe Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors Market by Country
7.2.1.3 Europe Structural Proteins Market by Country
7.2.1.4 Europe Membrane Proteins Market by Country
7.2.1.5 Europe Kinase Proteins & Regulatory Proteins Market by Country
7.2.1.6 Europe Immune Response Proteins Market by Country
7.2.1.7 Europe Others Market by Country
7.2.2 Europe Recombinant Proteins Market by End User
7.2.2.1 Europe Pharmaceutical & Biopharmaceutical Companies Market by Country
7.2.2.2 Europe Biotechnology Companies Market by Country
7.2.2.3 Europe Academic Research Institutes Market by Country
7.2.2.4 Europe Contract Research Organizations Market by Country
7.2.2.5 Europe Others Market by Country
7.2.3 Europe Recombinant Proteins Market by Application
7.2.3.1 Europe Drug Discovery & Development Market by Country
7.2.3.2 Europe Academic Research Studies Market by Country
7.2.3.3 Europe Biopharmaceutical Production Market by Country
7.2.3.4 Europe Diagnostics Market by Country
7.2.3.5 Europe Biotechnology Research Market by Country
7.2.3.6 Europe Others Market by Country
7.2.4 Europe Recombinant Proteins Market by Country
7.2.4.1 Germany Recombinant Proteins Market
7.2.4.1.1 Germany Recombinant Proteins Market by Product
7.2.4.1.2 Germany Recombinant Proteins Market by End User
7.2.4.1.3 Germany Recombinant Proteins Market by Application
7.2.4.2 UK Recombinant Proteins Market
7.2.4.2.1 UK Recombinant Proteins Market by Product
7.2.4.2.2 UK Recombinant Proteins Market by End User
7.2.4.2.3 UK Recombinant Proteins Market by Application
7.2.4.3 France Recombinant Proteins Market
7.2.4.3.1 France Recombinant Proteins Market by Product
7.2.4.3.2 France Recombinant Proteins Market by End User
7.2.4.3.3 France Recombinant Proteins Market by Application
7.2.4.4 Russia Recombinant Proteins Market
7.2.4.4.1 Russia Recombinant Proteins Market by Product
7.2.4.4.2 Russia Recombinant Proteins Market by End User
7.2.4.4.3 Russia Recombinant Proteins Market by Application
7.2.4.5 Spain Recombinant Proteins Market
7.2.4.5.1 Spain Recombinant Proteins Market by Product
7.2.4.5.2 Spain Recombinant Proteins Market by End User
7.2.4.5.3 Spain Recombinant Proteins Market by Application
7.2.4.6 Italy Recombinant Proteins Market
7.2.4.6.1 Italy Recombinant Proteins Market by Product
7.2.4.6.2 Italy Recombinant Proteins Market by End User
7.2.4.6.3 Italy Recombinant Proteins Market by Application
7.2.4.7 Rest of Europe Recombinant Proteins Market
7.2.4.7.1 Rest of Europe Recombinant Proteins Market by Product
7.2.4.7.2 Rest of Europe Recombinant Proteins Market by End User
7.2.4.7.3 Rest of Europe Recombinant Proteins Market by Application
7.3 Asia Pacific Recombinant Proteins Market
7.3.1 Asia Pacific Recombinant Proteins Market by Product
7.3.1.1 Asia Pacific Growth Factors & Chemokines Market by Country
7.3.1.2 Asia Pacific Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors Market by Country
7.3.1.3 Asia Pacific Structural Proteins Market by Country
7.3.1.4 Asia Pacific Membrane Proteins Market by Country
7.3.1.5 Asia Pacific Kinase Proteins & Regulatory Proteins Market by Country
7.3.1.6 Asia Pacific Immune Response Proteins Market by Country
7.3.1.7 Asia Pacific Others Market by Country
7.3.2 Asia Pacific Recombinant Proteins Market by End User
7.3.2.1 Asia Pacific Pharmaceutical & Biopharmaceutical Companies Market by Country
7.3.2.2 Asia Pacific Biotechnology Companies Market by Country
7.3.2.3 Asia Pacific Academic Research Institutes Market by Country
7.3.2.4 Asia Pacific Contract Research Organizations Market by Country
7.3.2.5 Asia Pacific Others Market by Country
7.3.3 Asia Pacific Recombinant Proteins Market by Application
7.3.3.1 Asia Pacific Drug Discovery & Development Market by Country
7.3.3.2 Asia Pacific Academic Research Studies Market by Country
7.3.3.3 Asia Pacific Biopharmaceutical Production Market by Country
7.3.3.4 Asia Pacific Diagnostics Market by Country
7.3.3.5 Asia Pacific Biotechnology Research Market by Country
7.3.3.6 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Recombinant Proteins Market by Country
7.3.4.1 China Recombinant Proteins Market
7.3.4.1.1 China Recombinant Proteins Market by Product
7.3.4.1.2 China Recombinant Proteins Market by End User
7.3.4.1.3 China Recombinant Proteins Market by Application
7.3.4.2 Japan Recombinant Proteins Market
7.3.4.2.1 Japan Recombinant Proteins Market by Product
7.3.4.2.2 Japan Recombinant Proteins Market by End User
7.3.4.2.3 Japan Recombinant Proteins Market by Application
7.3.4.3 India Recombinant Proteins Market
7.3.4.3.1 India Recombinant Proteins Market by Product
7.3.4.3.2 India Recombinant Proteins Market by End User
7.3.4.3.3 India Recombinant Proteins Market by Application
7.3.4.4 South Korea Recombinant Proteins Market
7.3.4.4.1 South Korea Recombinant Proteins Market by Product
7.3.4.4.2 South Korea Recombinant Proteins Market by End User
7.3.4.4.3 South Korea Recombinant Proteins Market by Application
7.3.4.5 Singapore Recombinant Proteins Market
7.3.4.5.1 Singapore Recombinant Proteins Market by Product
7.3.4.5.2 Singapore Recombinant Proteins Market by End User
7.3.4.5.3 Singapore Recombinant Proteins Market by Application
7.3.4.6 Malaysia Recombinant Proteins Market
7.3.4.6.1 Malaysia Recombinant Proteins Market by Product
7.3.4.6.2 Malaysia Recombinant Proteins Market by End User
7.3.4.6.3 Malaysia Recombinant Proteins Market by Application
7.3.4.7 Rest of Asia Pacific Recombinant Proteins Market
7.3.4.7.1 Rest of Asia Pacific Recombinant Proteins Market by Product
7.3.4.7.2 Rest of Asia Pacific Recombinant Proteins Market by End User
7.3.4.7.3 Rest of Asia Pacific Recombinant Proteins Market by Application
7.4 LAMEA Recombinant Proteins Market
7.4.1 LAMEA Recombinant Proteins Market by Product
7.4.1.1 LAMEA Growth Factors & Chemokines Market by Country
7.4.1.2 LAMEA Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors Market by Country
7.4.1.3 LAMEA Structural Proteins Market by Country
7.4.1.4 LAMEA Membrane Proteins Market by Country
7.4.1.5 LAMEA Kinase Proteins & Regulatory Proteins Market by Country
7.4.1.6 LAMEA Immune Response Proteins Market by Country
7.4.1.7 LAMEA Others Market by Country
7.4.2 LAMEA Recombinant Proteins Market by End User
7.4.2.1 LAMEA Pharmaceutical & Biopharmaceutical Companies Market by Country
7.4.2.2 LAMEA Biotechnology Companies Market by Country
7.4.2.3 LAMEA Academic Research Institutes Market by Country
7.4.2.4 LAMEA Contract Research Organizations Market by Country
7.4.2.5 LAMEA Others Market by Country
7.4.3 LAMEA Recombinant Proteins Market by Application
7.4.3.1 LAMEA Drug Discovery & Development Market by Country
7.4.3.2 LAMEA Academic Research Studies Market by Country
7.4.3.3 LAMEA Biopharmaceutical Production Market by Country
7.4.3.4 LAMEA Diagnostics Market by Country
7.4.3.5 LAMEA Biotechnology Research Market by Country
7.4.3.6 LAMEA Others Market by Country
7.4.4 LAMEA Recombinant Proteins Market by Country
7.4.4.1 Brazil Recombinant Proteins Market
7.4.4.1.1 Brazil Recombinant Proteins Market by Product
7.4.4.1.2 Brazil Recombinant Proteins Market by End User
7.4.4.1.3 Brazil Recombinant Proteins Market by Application
7.4.4.2 Argentina Recombinant Proteins Market
7.4.4.2.1 Argentina Recombinant Proteins Market by Product
7.4.4.2.2 Argentina Recombinant Proteins Market by End User
7.4.4.2.3 Argentina Recombinant Proteins Market by Application
7.4.4.3 UAE Recombinant Proteins Market
7.4.4.3.1 UAE Recombinant Proteins Market by Product
7.4.4.3.2 UAE Recombinant Proteins Market by End User
7.4.4.3.3 UAE Recombinant Proteins Market by Application
7.4.4.4 Saudi Arabia Recombinant Proteins Market
7.4.4.4.1 Saudi Arabia Recombinant Proteins Market by Product
7.4.4.4.2 Saudi Arabia Recombinant Proteins Market by End User
7.4.4.4.3 Saudi Arabia Recombinant Proteins Market by Application
7.4.4.5 South Africa Recombinant Proteins Market
7.4.4.5.1 South Africa Recombinant Proteins Market by Product
7.4.4.5.2 South Africa Recombinant Proteins Market by End User
7.4.4.5.3 South Africa Recombinant Proteins Market by Application
7.4.4.6 Nigeria Recombinant Proteins Market
7.4.4.6.1 Nigeria Recombinant Proteins Market by Product
7.4.4.6.2 Nigeria Recombinant Proteins Market by End User
7.4.4.6.3 Nigeria Recombinant Proteins Market by Application
7.4.4.7 Rest of LAMEA Recombinant Proteins Market
7.4.4.7.1 Rest of LAMEA Recombinant Proteins Market by Product
7.4.4.7.2 Rest of LAMEA Recombinant Proteins Market by End User
7.4.4.7.3 Rest of LAMEA Recombinant Proteins Market by Application
Chapter 8. Company Profiles
8.1 Bio-Techne Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.3 Merck Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Bio-Rad laboratories, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Abcam plc
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Genscript Biotech Corporation
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional & Segmental Analysis
8.6.4 Research & Development Expenses
8.7 Miltenyi Biotech B.V. & Co. KG
8.7.1 Company Overview
8.8 Proteintech Group, Inc.
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Acquisition and Mergers:
8.9 BPS Bioscience, Inc.
8.9.1 Company Overview
8.10. RayBiotech Life, Inc.
8.10.1 Company Overview
Companies Mentioned
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Methodology
LOADING...
